- Home
- CANF vs GSUN Comparison
CANF vs GSUN Comparison
Compare CANF & GSUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GSUN
- Stock Information
- Founded
- CANF 1994
- GSUN 1997
- Country
- CANF Israel
- GSUN China
- Employees
- CANF N/A
- GSUN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GSUN Other Consumer Services
- Sector
- CANF Health Care
- GSUN Real Estate
- Exchange
- CANF Nasdaq
- GSUN Nasdaq
- Market Cap
- CANF 13.5M
- GSUN 6.4M
- IPO Year
- CANF N/A
- GSUN 2022
- Fundamental
- Price
- CANF $1.03
- GSUN $2.80
- Analyst Decision
- CANF Strong Buy
- GSUN
- Analyst Count
- CANF 2
- GSUN 0
- Target Price
- CANF $14.00
- GSUN N/A
- AVG Volume (30 Days)
- CANF 83.3K
- GSUN 74.0K
- Earning Date
- CANF 08-29-2025
- GSUN 08-01-2025
- Dividend Yield
- CANF N/A
- GSUN N/A
- EPS Growth
- CANF N/A
- GSUN N/A
- EPS
- CANF N/A
- GSUN N/A
- Revenue
- CANF $674,000.00
- GSUN $10,159,020.00
- Revenue This Year
- CANF $461.72
- GSUN N/A
- Revenue Next Year
- CANF N/A
- GSUN N/A
- P/E Ratio
- CANF N/A
- GSUN N/A
- Revenue Growth
- CANF N/A
- GSUN 65.04
- 52 Week Low
- CANF $0.98
- GSUN $2.19
- 52 Week High
- CANF $4.69
- GSUN $8.94
- Technical
- Relative Strength Index (RSI)
- CANF 42.43
- GSUN 44.29
- Support Level
- CANF $1.00
- GSUN $2.56
- Resistance Level
- CANF $1.05
- GSUN $3.46
- Average True Range (ATR)
- CANF 0.02
- GSUN 0.22
- MACD
- CANF 0.00
- GSUN 0.03
- Stochastic Oscillator
- CANF 40.00
- GSUN 37.01
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GSUN Golden Sun Education Group Limited
Golden Sun Health Technology Group Ltd is a holding company. Along with its subsidiaries, it is engaged in the provision of education services and e-commerce business in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistics and consulting services. It has also established its wellness brands and an e-commerce platform to promote and sell wellness products. The company operates in the following segments; Education, which generates maximum revenue, and E-commerce.